Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2020 08:00 ET | Source: Cellectar Biosciences

Cellectar Announces Poster Presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) Annual Meeting

FLORHAM PARK, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
July 21, 2020 08:00 ET | Source: Cellectar Biosciences

Cellectar Announces Poster Presentation of Clinical Data at the American Association of Cancer Research (AACR) Annual Meeting

FLORHAM PARK, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
July 01, 2020 08:00 ET | Source: Cellectar Biosciences

Cellectar Appoints Dr. John Friend as Chief Medical Officer

FLORHAM PARK, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 11, 2020 08:30 ET | Source: Cellectar Biosciences

Cellectar to be Granted EU Patent for Phospholipid Ether (PLE) Analogs as Cancer-Targeting Drug Vehicles

FLORHAM PARK, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 05, 2020 16:01 ET | Source: Cellectar Biosciences

Cellectar Biosciences Announces Closing of $20 Million Underwritten Public Offering

FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of...
June 03, 2020 09:00 ET | Source: Cellectar Biosciences

Cellectar Biosciences Announces Pricing of $20 Million Underwritten Public Offering

FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
June 01, 2020 08:00 ET | Source: Cellectar Biosciences

Cellectar Granted SME Status by the European Medicines Agency

FLORHAM PARK, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 26, 2020 07:45 ET | Source: Cellectar Biosciences

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 14, 2020 08:00 ET | Source: Cellectar Biosciences

Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131

FLORHAM PARK, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
May 07, 2020 08:15 ET | Source: Cellectar Biosciences

Cellectar Reports First Quarter 2020 Financial Results and Provides a Corporate Update

FLORHAM PARK, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...